BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE and BONE DENSITY DECREASED

Overview

BONE DENSITY DECREASED is the #1 most commonly reported adverse reaction for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, manufactured by Gilead Sciences, Inc.. There are 6,535 FDA adverse event reports linking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE to BONE DENSITY DECREASED. This represents approximately 10.4% of all 62,897 adverse event reports for this drug.

Patients taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE who experience bone density decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

BONE DENSITY DECREASED is a frequently reported adverse event for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, accounting for a significant proportion of all reports.

Other Side Effects of BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE

In addition to bone density decreased, the following adverse reactions have been reported for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE:

• CHRONIC KIDNEY DISEASE — 3,595 reports
• BONE LOSS — 3,431 reports
• TOOTH LOSS — 3,376 reports
• OSTEONECROSIS — 3,353 reports
• MULTIPLE FRACTURES — 3,121 reports
• RENAL FAILURE — 2,982 reports
• OSTEOPOROSIS — 2,751 reports
• PAIN — 2,531 reports
• RENAL INJURY — 2,478 reports
• EMOTIONAL DISTRESS — 2,425 reports

Other Drugs Associated with BONE DENSITY DECREASED

The following drugs have also been linked to bone density decreased in FDA adverse event reports:

Does BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE cause BONE DENSITY DECREASED?

BONE DENSITY DECREASED has been reported as an adverse event in 6,535 FDA reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is BONE DENSITY DECREASED with BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE?

BONE DENSITY DECREASED accounts for approximately 10.4% of all adverse event reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, making it one of the most commonly reported side effect.

What should I do if I experience BONE DENSITY DECREASED while taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE?

If you experience bone density decreased while taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages